New diabetes drug PG-102 faces off against semaglutide in Mid-Stage trial
Disease control
Not yet recruiting
This study tests a new medicine called PG-102 in 80 adults with type 2 diabetes. It compares PG-102 to a placebo and to an existing drug, semaglutide, over 24 weeks. The main goal is to see if PG-102 lowers blood sugar levels better than placebo. Researchers will also check its s…
Phase: PHASE2 • Sponsor: ProGen. Co., Ltd. • Aim: Disease control
Last updated May 16, 2026 07:48 UTC